Literature DB >> 33377994

Pro-inflammatory cytokines, but not brain- and extracellular matrix-derived proteins, are increased in the plasma following electrically induced kindling of seizures.

Natalia Chmielewska1, Piotr Maciejak2, Bartosz Osuch2, Miron B Kursa3, Janusz Szyndler4.   

Abstract

BACKGROUND: The aim of the study was to evaluate the brain-derived proteins, extracellular matrix-derived protein and cytokines as potential peripheral biomarkers of different susceptibility to seizure development in an animal model of epilepsy evoked by chronic focal electrical stimulation of the brain.
METHODS: The plasma levels of IL-1β (interleukin 1β), IL-6 (interleukin 6), UCH-L1 (ubiquitin C-terminal hydrolase 1), MMP-9 (matrix metalloproteinase 9), and GFAP (glial fibrillary acidic protein) were assessed. The peripheral concentrations of the selected proteins were analyzed according to the status of kindling and seizure severity parameters. In our study, increased concentrations of plasma IL-1β and IL-6 were observed in rats subjected to hippocampal kindling compared to sham-operated rats.
RESULTS: Animals that developed tonic-clonic seizures after the last stimulation had higher plasma concentrations of IL-1β and IL-6 than sham-operated rats and rats that did not develop seizure. Elevated levels of IL-1β and IL-6 were observed in rats that presented more severe seizures after the last five stimulations compared to sham-operated animals. A correlation between plasma IL-1β and IL-6 concentrations was also found. On the other hand, the plasma levels of the brain-derived proteins UCH-L1, MMP-9, and GFAP were unaffected by kindling status and seizure severity parameters.
CONCLUSIONS: The plasma concentrations of IL-1β and IL-6 may have potential utility as peripheral biomarkers of immune system activation in the course of epilepsy and translational potential for future clinical use. Surprisingly, markers of cell and nerve ending damage (GFAP, UCH-L1 and MMP-9) may have limited utility.

Entities:  

Keywords:  GFAP; Hippocampal kindling; MMP-9; Peripheral inflammation; Seizure susceptibility biomarker; UCH-L1

Year:  2020        PMID: 33377994      PMCID: PMC7994222          DOI: 10.1007/s43440-020-00208-w

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  51 in total

1.  Effects of lipopolysaccharide on blood-brain barrier permeability during pentylenetetrazole-induced epileptic seizures in rats.

Authors:  Nadir Arican; Mehmet Kaya; Rivaze Kalayci; Hafize Uzun; Bulent Ahishali; Bilge Bilgic; Imdat Elmas; Mutlu Kucuk; Candan Gurses; Mustafa Uzun
Journal:  Life Sci       Date:  2006-01-24       Impact factor: 5.037

2.  Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus.

Authors:  M G De Simoni; C Perego; T Ravizza; D Moneta; M Conti; F Marchesi; A De Luigi; S Garattini; A Vezzani
Journal:  Eur J Neurosci       Date:  2000-07       Impact factor: 3.386

3.  The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus.

Authors:  Gyung W Kim; Hyun-Jeong Kim; Kyoung-Joo Cho; Hyun-Woo Kim; Yang-Je Cho; Byung I Lee
Journal:  Neurobiol Dis       Date:  2009-07-23       Impact factor: 5.996

4.  Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children.

Authors:  Christina A Gurnett; Michael Landt; Michael Wong
Journal:  Epilepsia       Date:  2003-11       Impact factor: 5.864

5.  Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients.

Authors:  Ling-Yan Mao; Jing Ding; Wei-Feng Peng; Yu Ma; Yu-Hao Zhang; Wei Fan; Xin Wang
Journal:  Epilepsia       Date:  2013-08-14       Impact factor: 5.864

6.  Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release.

Authors:  Peter Thornton; Emmanuel Pinteaux; Rosemary M Gibson; Stuart M Allan; Nancy J Rothwell
Journal:  J Neurochem       Date:  2006-07       Impact factor: 5.372

Review 7.  Role of brain inflammation in epileptogenesis.

Authors:  Jieun Choi; Sookyong Koh
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

8.  Matrix metalloproteinases and epileptogenesis.

Authors:  Chrysanthy Ikonomidou
Journal:  Mol Cell Pediatr       Date:  2014-11-04

Review 9.  Immune mechanisms in epileptogenesis.

Authors:  Dan Xu; Stephen D Miller; Sookyong Koh
Journal:  Front Cell Neurosci       Date:  2013-11-08       Impact factor: 5.505

Review 10.  Microglia and CNS Interleukin-1: Beyond Immunological Concepts.

Authors:  Xiaoyu Liu; Ning Quan
Journal:  Front Neurol       Date:  2018-01-23       Impact factor: 4.003

View more
  4 in total

1.  Corticotropin Releasing Factor Mediates KCa3.1 Inhibition, Hyperexcitability, and Seizures in Acquired Epilepsy.

Authors:  Manindra Nath Tiwari; Sandesh Mohan; Yoav Biala; Oded Shor; Felix Benninger; Yoel Yaari
Journal:  J Neurosci       Date:  2022-06-22       Impact factor: 6.709

2.  Cattle Bile Arisaema Aqueous Extracts Protect Against Febrile Seizures in Rats Through Regulating Neurotransmitters and Suppressing Neuroinflammation.

Authors:  Fa-Zhi Su; Chen-Xi Bai; Yumeng Luo; Wen-Sen Zhang; Na Cui; Yang-Yang Wang; Yan-Ping Sun; Wen-Bo Zhu; Ming-Yang Zhao; Bing-You Yang; Hai-Xue Kuang; Qiu-Hong Wang
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

Review 3.  Advances in the Development of Biomarkers for Poststroke Epilepsy.

Authors:  Mengke Liang; Liren Zhang; Zhi Geng
Journal:  Biomed Res Int       Date:  2021-04-17       Impact factor: 3.411

4.  Anticonvulsant effect of pterostilbene and its influence on the anxiety- and depression-like behavior in the pentetrazol-kindled mice: behavioral, biochemical, and molecular studies.

Authors:  Dorota Nieoczym; Katarzyna Socała; Agnieszka Zelek-Molik; Mateusz Pieróg; Katarzyna Przejczowska-Pomierny; Małgorzata Szafarz; Elżbieta Wyska; Irena Nalepa; Piotr Wlaź
Journal:  Psychopharmacology (Berl)       Date:  2021-08-01       Impact factor: 4.415

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.